Literature DB >> 23490375

Towards realistic estimates of HCV incidence in Egypt.

R Breban1, W Doss, G Esmat, M Elsayed, M Hellard, P Ayscue, M Albert, A Fontanet, M K Mohamed.   

Abstract

Accurate incidence estimates are essential for quantifying hepatitis C virus (HCV) epidemic dynamics and monitoring the effectiveness of public health programmes, as well as for predicting future burden of disease and planning patient care. In Egypt, the country with the largest HCV epidemic worldwide, two modelling studies have estimated age-specific incidence rates that, applied to the age pyramid, would correspond to more than 500 000 Egyptians getting infected annually. This is in contrast to figures of the Egyptian Ministry of Health and Population that estimates new infections to be approximately 100 000 per year. We performed new analyses of nationwide data to examine the modelling assumptions that led to these estimates. Thus, we found that the key assumption of these models of a stationary epidemic is invalid. We propose an alternate approach to estimating incidence based on analysing cohort data; we find that the number of annual new infections is <150 000.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23490375     DOI: 10.1111/j.1365-2893.2012.01650.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  25 in total

Review 1.  Milestones along the road of infection prevention in Egypt.

Authors:  H A El-Mahallawy; L M Mohsen; M Wassef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-01       Impact factor: 3.267

2.  Wide Sexual Dimorphism of Hepatocellular Carcinoma Presentation in Algeria.

Authors:  Yazid Chikhi; Salima Cheraitia; Rachid Ould Gougam; Fadila Lounes; Chahrazed Zemmouchi; Nassila Belal; Maroua Bendaoud; Sonia Ait Younes; Aicha Bensalem; Saadi Berkane; Hocine Asselah; Pascal Pineau; Mustapha Lahcene
Journal:  Gastrointest Tumors       Date:  2019-08-30

3.  Hepatitis C Virus Exposure Rate among Health-care Workers in Rural Lower Egypt Governorates.

Authors:  Ashraf Elbahrawy; Ahmed Elwassief; Abdallah Mahmoud Abdallah; Arafat Kasem; Sadek Mostafa; Khaled Makboul; Mohamed Salah Ali; Ahmed Alashker; Ahmed Maher Eliwa; Hossam Shahbah; Mohamed Abdellah Othman; Mohamed Hanafy Morsy; Mohamed Ali Abdelbaseer; Hafez Abdelhafeez
Journal:  J Transl Int Med       Date:  2017-09-30

Review 4.  Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus.

Authors:  Ashraf Tabll; Aymn T Abbas; Sherif El-Kafrawy; Ahmed Wahid
Journal:  World J Hepatol       Date:  2015-10-08

5.  Modelling the prevalence of hepatitis C virus amongst blood donors in Libya: An investigation of providing a preventive strategy.

Authors:  Mohamed A Daw; Amira Shabash; Abdallah El-Bouzedi; Aghnya A Dau; Moktar Habas
Journal:  World J Virol       Date:  2016-02-12

6.  Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma.

Authors:  Nermin A Ali; Nadia M Hamdy; Abdullah A Gibriel; Hala O El Mesallamy
Journal:  Arch Virol       Date:  2021-04-01       Impact factor: 2.574

Review 7.  Hepatitis C genotype 4: The past, present, and future.

Authors:  Tawhida Y Abdel-Ghaffar; Mostafa M Sira; Suzan El Naghi
Journal:  World J Hepatol       Date:  2015-12-08

8.  Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C.

Authors:  Hala Rady Ahmed; Nancy G F M Waly; Rehab Mahmoud Abd El-Baky; Ramadan Yahia; Helal F Hetta; Amr M Elsayed; Reham Ali Ibrahem
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

Review 9.  The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis.

Authors:  Yousra A Mohamoud; Ghina R Mumtaz; Suzanne Riome; Dewolfe Miller; Laith J Abu-Raddad
Journal:  BMC Infect Dis       Date:  2013-06-24       Impact factor: 3.090

10.  Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.

Authors:  Asmaa M Abdel-Aziz; Mohamed A Ibrahim; Azza A El-Sheikh; Maha Y Kamel; Nagwa M Zenhom; Salam Abdel-Raheim; Hisham Abdelhaleem
Journal:  J Clin Exp Hepatol       Date:  2017-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.